MannKind and One Drop Partner to Launch the A-ONE Clinical Trial
August 07 2017 - 9:30AM
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and
One Drop today announced the first step of their collaboration with
the launch of the A-ONE study, a randomized controlled trial
investigating the use of Afrezza® inhaled insulin and One Drop's
integrated digital diabetes care platform.
In May 2017, MannKind and One Drop announced a memorandum of
understanding to explore collaborations related to One Drop |
Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and
test strips, One Drop | Experts coaching service) and Afrezza®,
MannKind's inhaled rapid-acting mealtime insulin. One goal of the
collaboration is to identify ways of simplifying the complexity of
starting and staying on mealtime insulin along with Customized
Coaching to help people achieve their A1C goals.
Appropriate people with type 2 diabetes who meet inclusion
criteria will be randomized to one of two treatment arms:
Afrezza® with One Drop | Premium – or – One Drop | Premium
alone. Changes in hemoglobin A1C, quality of life, self-care,
treatment satisfaction, and other metrics will be assessed.
People with type 2 diabetes interested in learning more
should email Aone@onedrop.today.
Dr. Raymond Urbanski, Chief Medical Officer of MannKind
Corporation, said, “This study is intended to evaluate whether
combining a solutions-oriented digital disease management platform
like One Drop with an innovative drug like Afrezza® will provide
patients with an improved ability to manage their diabetes.”
“One Drop is a unique, fully integrated solution with the
prospects of a huge health benefit,” says Dr. Chandra Osborn, VP of
Health and Behavioral Informatics at One Drop. “We know each piece
of the puzzle works, and now we want to see how well they work
together. With 9 peer-reviewed outcomes shared at medical meetings
and a paper in press at JMIR Diabetes, One Drop is committed to
delivering the most effective diabetes management solution in the
market. The combination of One Drop with inhaled insulin could
offer consumers, health care providers, and payers a potentially
powerful solution with unprecedented benefits.”
“Diabetes technology is evolving in a very exciting way,” said
Jeff Dachis, CEO and Founder of One Drop. “But not surprisingly for
the vast majority of people with diabetes worldwide, expensive
sensors, automated insulin delivery solutions, or call center
approaches to care can create barriers and challenges to effective
disease management. However, we are excited to evaluate whether a
completely integrated digital diabetes therapeutics platform —
encompassing evidence-based interventions, ADA-recognized diabetes
education and coaching, wireless blood glucose tracking,
user-centered design, robust data science, and an innovative
pharmaceutical product like MannKind’s Afrezza — can deliver
improved health outcomes at a fraction of the cost of current
standards of care.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the
discovery, development and commercialization of therapeutic
products for patients with diseases such as diabetes. MannKind
maintains a website at www.mannkindcorp.com to which MannKind
regularly posts copies of its press releases as well as additional
information about MannKind. Interested persons can subscribe on the
MannKind website to e-mail alerts that are sent automatically when
MannKind issues press releases, files its reports with the
Securities and Exchange Commission or posts certain other
information to the website. For more information about Afrezza,
please visit www.afrezza.com.
ABOUT ONE DROP
One Drop (Informed Data Systems Inc.) is a digital health
company harnessing the power of mobile computing and data science
to transform the lives of everyone with diabetes worldwide.
The One Drop platform is evidence-based and clinically
effective. It brings affordable, accessible diabetes care to
everyone with diabetes and a smartphone, as well as their insurers
and health care providers. One Drop's current offerings
include:
- One Drop | Chrome: One Drop's FDA-approved,
CE-certified Bluetooth wireless blood glucose monitoring system,
which meets the highest standards of clinical accuracy and
wirelessly transmits blood glucose data to the cloud via the One
Drop | Mobile app for iOS and Android.
- One Drop | Plus: One Drop's newest
subscription offerings, providing 50 to 100 blood glucose test
strips per month for One Drop | Chrome and unlimited coaching via
One Drop | Experts, starting at $13 per month.
- One Drop | Premium: One Drop's unlimited
subscription, providing unlimited blood glucose test strips for One
Drop | Chrome and unlimited coaching via One Drop | Experts,
starting at $33 per month.
- One Drop | Experts: One Drop's 24/7,
on-demand, digital diabetes education and coaching service,
available as a standalone subscription, starting at $11 per month.*
Each One Drop | Experts subscriber has his/her own “Expert”
(Certified Diabetes Educator) available 24/7 for guidance, support,
and anytime care. Experts deliver personalized digital therapeutics
programs, including ADA-recognized diabetes education, to help
people with diabetes define and achieve their health management
goals. Subscribers can communicate with their Experts anytime via
in-app chat; all data recorded in the app is available to Experts
in real-time, allowing them to provide personalized behavioral
guidance when subscribers need it most — no appointments
necessary.
- One Drop | Mobile: One Drop's free,
award-winning, cloud-based diabetes management solution delivered
entirely via mobile app on iOS and Android. One Drop | Mobile
provides real-time and historical blood glucose data and analytics
to people with diabetes and their healthcare providers, allowing
both to see relationships between specific health behaviors and
health outcomes. One Drop | Mobile includes a fully-featured Apple
WatchOS app for logging and analyzing diabetes data on the go. One
Drop | Mobile is the only diabetes management platform that offers
comprehensive self-care, peer-support, and expert support all in
one place.
- One Drop | Professional: One Drop's
HIPPA-compliant enterprise solution for insurers, healthcare
provider networks, self-insured employers, and drug/device
manufacturers seeking to dramatically improve health outcomes and
lower the cost of caring for people with diabetes. One Drop |
Professional delivers real-time data, real-time messaging, custom
branding, custom content delivery, custom educational support,
EMR/EHR integration, and the most affordable, effective, turnkey
diabetes solution in market.
One Drop | Chrome is sold exclusively by One Drop (iOS, Android,
and http://onedrop.today/), Amazon (http://www.amazon.com), and
Apple (http://store.apple.com). One Drop's consumer subscription
services are available for purchase in-app (iOS and Android) and at
http://onedrop.today. The One Drop | Mobile solution is available
for free download worldwide (iOS and Android). For more
information, contact just@onedrop.today. *The American Diabetes
Association recognizes this education service as meeting the
National Standards for Diabetes Self-Management Education and
Support.
MannKind Contact:
Rose Alinaya SVP, Investor Relations
661-775-5300
IR@mannkindcorp.com
One Drop Contact:
Rachel M. Sanchez
917-342-2892
rachel@onedrop.today
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024